Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting

May 23, 2024

https://www.globenewswire.com/news-release/2024/05/23/2887675/0/en/Werewolf-Therapeutics-to-Present-Updated-Data-from-Phase-1-1b-Clinical-Trial-of-WTX-124-as-Monotherapy-and-in-Combination-with-Pembrolizumab-in-Solid-Tumors-at-2024-ASCO-Annual-Mee.html

– Updated single agent dose escalation data continues to demonstrate that WTX-124 is well tolerated and clinically active in patients with checkpoint inhibitor therapy relapsed/refractory cancers –

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.